Neuralstem, Inc. (CUR)’s Shares Opened 4.83% Higher On Preclinical Alzheimer’s Data

How are hedge funds trading Neuralstem, Inc. (NYSEAMEX:CUR)?

The hedge fund sentiment is slightly bearish as two out of three hedge fund managers have reduced their holdings in the biotechnology company.

The largest stockholder of the biopharmaceutical company, Ken Griffin’s Citadel Investment Group, boosted its equity investment by 860% with the ownership of 250,896 shares of the company along with PUT and CALL investments of 23,500 and 51,300 shares respectively. David E. Shaw’s D.E.Shaw has reduced its holdings in the company by 57% with 64,305 shares and net investments of $122,000. Cliff Asness’ AQR Capital Management is another investor with a bearish outlook, as it dropped 73% of its stake in the pharmaceutical company with current ownership of 35,000 shares valued at $67,000.

Despite the bearish outlook of hedge fund managers, the pharmaceutical company has gained support from long-term investors and its successful clinical results present the right opportunity to invest in the company. However, we don’t think the hedge fund sentiment is strong enough to warrant a buy recommendation.

Disclosure: None